Intracerebroventricular anaerobic dopamine in Parkinson's disease with L-dopa-related complications: a phase 1/2 randomized-controlled trial.
Level 2 - randomized trial
Randomized controlled crossover trial (Phase 2)
PubMed 39775041 · doi:10.1038/s41591-024-03428-2
What was done
Researchers evaluated continuous intracerebroventricular delivery of anaerobic dopamine (A-dopamine) via an abdominal pump and catheter into the third ventricle for Parkinson's disease patients with L-dopa-related complications. Following an open-label Phase 1 safety evaluation in 12 patients, a randomized, controlled, open-label, crossover Phase 2 trial was conducted in 9 patients comparing 1 month of A-dopamine to 1 month of optimized oral therapy. The primary endpoint was a blinded measurement of percentage of time over target (time spent in dyskinesia or bradykinesia) recorded via home actimetry wristwatches, alongside home motor diaries.
What was found
In Phase 1 (n = 12), no serious adverse reactions were attributed to A-dopamine. In the Phase 2 crossover trial (n = 9), A-dopamine significantly reduced actimetry-measured time over target compared to optimized oral treatment alone (P = 0.027), with a median within-patient difference of -10.4 (Hedges' g = -0.62, 95% CI: -1.43 to -0.08). Home diary measures also demonstrated significant improvement (no specific figures reported in abstract).
Why it matters
Direct intracerebroventricular delivery of anaerobic dopamine bypasses peripheral pharmacokinetics and the blood-brain barrier, providing initial proof-of-concept for continuous central dopamine replacement to stabilize motor fluctuations.
Limits
The study is limited by an extremely small sample size (9 patients in the crossover phase), brief treatment duration (1 month per arm), and an open-label intervention design. Surgical risks, long-term catheter/pump safety, and durability of effect remain uncharacterized.
Cited by
- supports Pure dopamine cannot cross the blood-brain barrier when ingested or administered peripherally, whereas L-DOPA does cross the blood-brain barrier.